SG11201404888SA - Combinations of histone deacetylase inhibitor and pazopanib and uses thereof - Google Patents

Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Info

Publication number
SG11201404888SA
SG11201404888SA SG11201404888SA SG11201404888SA SG11201404888SA SG 11201404888S A SG11201404888S A SG 11201404888SA SG 11201404888S A SG11201404888S A SG 11201404888SA SG 11201404888S A SG11201404888S A SG 11201404888SA SG 11201404888S A SG11201404888S A SG 11201404888SA
Authority
SG
Singapore
Prior art keywords
pazopanib
combinations
histone deacetylase
deacetylase inhibitor
inhibitor
Prior art date
Application number
SG11201404888SA
Inventor
Sriram Balasubramanian
Tarak D Mody
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of SG11201404888SA publication Critical patent/SG11201404888SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201404888SA 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof SG11201404888SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600491P 2012-02-17 2012-02-17
US201261602544P 2012-02-23 2012-02-23
PCT/US2013/026462 WO2013123413A2 (en) 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Publications (1)

Publication Number Publication Date
SG11201404888SA true SG11201404888SA (en) 2014-09-26

Family

ID=48984895

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404888SA SG11201404888SA (en) 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Country Status (12)

Country Link
US (1) US20150335609A1 (en)
EP (1) EP2814493A4 (en)
JP (1) JP2015507020A (en)
KR (1) KR20140129164A (en)
CN (1) CN104244952A (en)
AU (1) AU2013221298A1 (en)
CA (1) CA2864736A1 (en)
HK (1) HK1204998A1 (en)
MX (1) MX2014009892A (en)
RU (1) RU2014137190A (en)
SG (1) SG11201404888SA (en)
WO (1) WO2013123413A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079699A4 (en) * 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
DK3594343T3 (en) * 2015-07-23 2021-06-28 Inst Curie USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS FOR CANCER OF CANCER
WO2017053823A1 (en) * 2015-09-25 2017-03-30 Pharmacyclics Llc Treatment using hdac inhibitors and immunotherapy
EP3612177A4 (en) * 2017-04-21 2021-01-13 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
JP7227777B2 (en) * 2019-02-04 2023-02-22 キヤノン株式会社 Imaging device
KR20220018727A (en) 2020-08-07 2022-02-15 계명대학교 산학협력단 Composition for preventing or treating of obesity comprising pazopanib or pharmaceutically acceptable salts thereof
EP4255436A1 (en) * 2020-12-07 2023-10-11 HHT Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611088B1 (en) * 2003-04-07 2009-06-17 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
JP2007532658A (en) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション How to treat cancer
US20090005406A1 (en) * 2005-11-29 2009-01-01 Smithkline Beecham Corporation Cancer Treatment Method
EA201170821A1 (en) * 2008-12-15 2011-12-30 Эли Лилли Энд Компани ENASTAURIN FOR CANCER TREATMENT
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UY33367A (en) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR DEVELOPMENT
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations

Also Published As

Publication number Publication date
RU2014137190A (en) 2016-04-10
WO2013123413A2 (en) 2013-08-22
US20150335609A1 (en) 2015-11-26
AU2013221298A1 (en) 2014-08-28
EP2814493A2 (en) 2014-12-24
HK1204998A1 (en) 2015-12-11
EP2814493A4 (en) 2015-07-22
CN104244952A (en) 2014-12-24
JP2015507020A (en) 2015-03-05
CA2864736A1 (en) 2013-08-22
MX2014009892A (en) 2015-02-12
KR20140129164A (en) 2014-11-06

Similar Documents

Publication Publication Date Title
HRP20180953T1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
HRP20181381T1 (en) Novel histone deacetylase inhibitors
EP2701699A4 (en) Inhibitors of histone deacetylase
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
HK1218067A1 (en) Histone deacetylase inhibitors
EP2680694A4 (en) Histone deacetylase inhibitors
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
HK1220407A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
IL227379A0 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
IL257069B (en) Inhibitors of apoptosis and uses thereof
IL236686A0 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1220406A1 (en) Histone deacetylase inhibitors and compositions
HK1220461A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1160443A1 (en) Histone deacetylase inhibitors